Immune regulation and the tumor microenvironment in anti-PD-1/PDL-1 and anti-CTLA-4 therapies for cancer immune evasion : A bibliometric analysis
This study aims to conduct a bibliometric analysis, employing visualization tools to examine literature pertaining to tumor immune evasion related to anti-CTLA-4 and anti-PD-1/PD-L1 therapy from 1999 to 2022. A special emphasis is placed on the interplay between tumor microenvironment, signaling pathways, immune cells and immune evasion, with data sourced from the Web of Science core collection (WoSCC). Advanced tools, including VOSviewer, Citespace, and Scimago Graphica, were utilized to analyze various parameters, such as co-authorship/co-citation patterns, regional contributions, journal preferences, keyword co-occurrences, and significant citation bursts. Out of 4778 publications reviewed, there was a marked increase in research focusing on immune evasion, with bladder cancer being notably prominent. Geographically, China, the USA, and Japan were the leading contributors. Prestigious institutions like MD Anderson Cancer Center, Harvard Medical School, Fudan University, and Sun Yat Sen University emerged as major players. Renowned journals in this domain included Frontiers in Immunology, Cancers, and Frontiers in Oncology. Ehen LP and Wang W were identified as prolific authors on this topic, while Topalian SL stood out as one of the most cited. Research current situation is notably pivoting toward challenges like immunotherapy resistance and the intricate signaling pathways driving drug resistance. This bibliometric study seeks to provide a comprehensive overview of past and current research trends, emphasizing the potential role of tumor microenvironment, signaling pathways and immune cells in the context of immune checkpoint inhibitors (ICIs) and tumor immune evasion.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:20 |
|---|---|
| Enthalten in: |
Human vaccines & immunotherapeutics - 20(2024), 1 vom: 31. März, Seite 2318815 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Huang, Yi [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Bibliometrics |
|---|
| Anmerkungen: |
Date Completed 01.03.2024 Date Revised 01.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/21645515.2024.2318815 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369094433 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369094433 | ||
| 003 | DE-627 | ||
| 005 | 20240301232907.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240301s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/21645515.2024.2318815 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1313.xml |
| 035 | |a (DE-627)NLM369094433 | ||
| 035 | |a (NLM)38419524 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Huang, Yi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Immune regulation and the tumor microenvironment in anti-PD-1/PDL-1 and anti-CTLA-4 therapies for cancer immune evasion |b A bibliometric analysis |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.03.2024 | ||
| 500 | |a Date Revised 01.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a This study aims to conduct a bibliometric analysis, employing visualization tools to examine literature pertaining to tumor immune evasion related to anti-CTLA-4 and anti-PD-1/PD-L1 therapy from 1999 to 2022. A special emphasis is placed on the interplay between tumor microenvironment, signaling pathways, immune cells and immune evasion, with data sourced from the Web of Science core collection (WoSCC). Advanced tools, including VOSviewer, Citespace, and Scimago Graphica, were utilized to analyze various parameters, such as co-authorship/co-citation patterns, regional contributions, journal preferences, keyword co-occurrences, and significant citation bursts. Out of 4778 publications reviewed, there was a marked increase in research focusing on immune evasion, with bladder cancer being notably prominent. Geographically, China, the USA, and Japan were the leading contributors. Prestigious institutions like MD Anderson Cancer Center, Harvard Medical School, Fudan University, and Sun Yat Sen University emerged as major players. Renowned journals in this domain included Frontiers in Immunology, Cancers, and Frontiers in Oncology. Ehen LP and Wang W were identified as prolific authors on this topic, while Topalian SL stood out as one of the most cited. Research current situation is notably pivoting toward challenges like immunotherapy resistance and the intricate signaling pathways driving drug resistance. This bibliometric study seeks to provide a comprehensive overview of past and current research trends, emphasizing the potential role of tumor microenvironment, signaling pathways and immune cells in the context of immune checkpoint inhibitors (ICIs) and tumor immune evasion | ||
| 650 | 4 | |a Review | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a CLTA-4 | |
| 650 | 4 | |a Immune checkpoint inhibitors (ICIs) | |
| 650 | 4 | |a PD-1/PD-L1 | |
| 650 | 4 | |a bibliometrics | |
| 650 | 4 | |a immune evasion | |
| 700 | 1 | |a Chen, Zhijian |e verfasserin |4 aut | |
| 700 | 1 | |a Shen, Gang |e verfasserin |4 aut | |
| 700 | 1 | |a Fang, Shuogui |e verfasserin |4 aut | |
| 700 | 1 | |a Zheng, Junjiong |e verfasserin |4 aut | |
| 700 | 1 | |a Chi, Zepai |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Yuanfeng |e verfasserin |4 aut | |
| 700 | 1 | |a Zou, Yitong |e verfasserin |4 aut | |
| 700 | 1 | |a Gan, Qinghua |e verfasserin |4 aut | |
| 700 | 1 | |a Liao, Chengxiao |e verfasserin |4 aut | |
| 700 | 1 | |a Yao, Yuhui |e verfasserin |4 aut | |
| 700 | 1 | |a Kong, Jianqiu |e verfasserin |4 aut | |
| 700 | 1 | |a Fan, Xinxiang |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Human vaccines & immunotherapeutics |d 2012 |g 20(2024), 1 vom: 31. März, Seite 2318815 |w (DE-627)NLM21576823X |x 2164-554X |7 nnns |
| 773 | 1 | 8 | |g volume:20 |g year:2024 |g number:1 |g day:31 |g month:03 |g pages:2318815 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/21645515.2024.2318815 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 20 |j 2024 |e 1 |b 31 |c 03 |h 2318815 | ||